Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Tissue fibrosis is a key factor leading to disability and death worldwide; however, thus far, there are no approved treatments for fibrosis. Transforming growth factor (TGF)-β is a major pro-fibrotic cytokine, which is expected to become a target in the treatment of fibrosis; however, since TGF-β has a wide range of biological functions involving a variety of biological processes in the body, a slight change in TGF-β may have a systematic effect. Indiscriminate inhibition of TGF-β can lead to adverse reactions, which can affect the efficacy of treatment. Therefore, it has become very important to explore how both the TGF-β signaling pathway is inhibited and the safe and efficient TGF-β small molecule inhibitors or neutralizing antibodies are designed in the treatment of fibrotic diseases. In this review, we mainly discuss the key role of the TGF-β signaling pathway in fibrotic diseases, as well as the development of fibrotic drugs in recent years, and explore potential targets in the treatment of fibrotic diseases in order to guide subsequent drug development.

• Publication year

  2022

• Venue

  Immunologic research

• Publication date

  2022-02-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12026-022-09267-yPMID 35147920PMCID 9197809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel therapies emerging in oncology to target the TGF-β pathway

  2021cited by this paper
• Attenuation of Myocardial Fibrosis Using Molecular Hydrogen by Inhibiting the TGF-β Signaling Pathway in Spontaneous Hypertensive Rats.

  2021cited by this paper
• Transient Receptor Potential Melastatin 2 Enhances Vascular Reactivity During Development of Atherosclerosis in Mice.

  2021cited by this paper
• Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway

  2021cited by this paper
• Therapeutic Implications of TGFβ in Cancer Treatment: A Systematic Review

  2021cited by this paper
• 8-Gingerol Ameliorates Myocardial Fibrosis by Attenuating Reactive Oxygen Species, Apoptosis, and Autophagy via the PI3K/Akt/mTOR Signaling Pathway

  2021cited by this paper
• Next Generation Therapeutics for the Treatment of Myelofibrosis

  2021cited by this paper
• TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis

  2021cited by this paper
• Fibrosis: from mechanisms to medicines

  2020cited by this paper
• Silicosis: An Update and Guide for Clinicians.

  2020cited by this paper
• Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib

  2020cited by this paper
• TGFβ1-specific antibody spurs anti-tumour immunity

  2020cited by this paper
• Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

  2020cited by this paper
• Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation

  2020cited by this paper
• Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis

  2020cited by this paper
• Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer

  2020cited by this paper
• TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering

  2020cited by this paper
• Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

  2020cited by this paper
• Transforming Growth Factor-β Signaling in Immunity and Cancer.

  2019cited by this paper
• Glutaminolysis Epigenetically Regulates Antiapoptotic Gene Expression in Idiopathic Pulmonary Fibrosis Fibroblasts

  2019cited by this paper
• Keloid lesions show increased IL‐4/IL‐13 signaling and respond to Th2‐targeting dupilumab therapy

  2019cited by this paper
• Molecular Engineering of the TGF-β Signaling Pathway.

  2019cited by this paper
• Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis

  2019cited by this paper
• TGF-β1 - A truly transforming growth factor in fibrosis and immunity.

  2019cited by this paper
• Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway.

  2019cited by this paper
• Interleukin-17 pathways in systemic sclerosis-associated fibrosis

  2019cited by this paper
• TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019

  2019cited by this paper
• Specificity, versatility, and control of TGF-β family signaling

  2019cited by this paper
• Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues.

  2019cited by this paper
• Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis

  2019cited by this paper
• Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.

  2019cited by this paper
• Involvement of hydrogen sulfide in the progression of renal fibrosis

  2019cited by this paper
• Oral submucous fibrosis: A global challenge. Rising incidence, risk factors, management, and research priorities.

  2019cited by this paper
• Inhibition of Glutaminase 1 Attenuates Experimental Pulmonary Fibrosis.

  2019cited by this paper
• Human pentraxin 2 protein treatment for IPF.

  2019cited by this paper
• High Glucose Intake Exacerbates Autoimmunity through Reactive-Oxygen-Species-Mediated TGF-β Cytokine Activation.

  2019cited by this paper
• Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.

  2019cited by this paper
• Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking.

  2018cited by this paper
• Mechanistic insight into contextual TGF-β signaling.

  2018cited by this paper
• TGF-&bgr; family co-receptor function and signaling

  2018cited by this paper
• TGFβ signaling and the control of myofibroblast differentiation: Implications for chronic inflammatory disorders

  2018cited by this paper
• Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

  2018cited by this paper
• Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts

  2018cited by this paper
• AMPK Activation Regulates LTBP4-Dependent TGF-β1 Secretion by Pro-inflammatory Macrophages and Controls Fibrosis in Duchenne Muscular Dystrophy.

  2018cited by this paper
• The SMAD2/3 interactome reveals that TGFβ controls m6A mRNA methylation in pluripotency

  2018cited by this paper
• TGF-β1 Signaling and Tissue Fibrosis.

  2018cited by this paper
• New insights into TGF-β/Smad signaling in tissue fibrosis.

  2018cited by this paper
• IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis

  2018cited by this paper
• Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

  2018cited by this paper
• PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production

  2018cited by this paper
• M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

  2018cited by this paper
• RhoA, Rac1, and Cdc42 differentially regulate αSMA and collagen I expression in mesenchymal stem cells

  2018cited by this paper
• Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis

  2017cited by this paper
• Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

  2017cited by this paper
• Glutaminolysis Promotes Collagen Translation and Stability via &agr;‐Ketoglutarate‐mediated mTOR Activation and Proline Hydroxylation

  2017cited by this paper
• Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis

  2017cited by this paper
• The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis

  2017cited by this paper
• Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis.

  2017cited by this paper
• Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure

  2017cited by this paper
• Targeting lysyl oxidase reduces peritoneal fibrosis

  2017cited by this paper
• Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment

  2017cited by this paper
• The Role of Trypsin:Chymotrypsin in Tissue Repair

  2017cited by this paper
• Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.

  2017cited by this paper
• Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013.

  2017cited by this paper
• Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis

  2017cited by this paper
• Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis

  2017cited by this paper
• PDGF in organ fibrosis.

  2017cited by this paper
• [ARTIFICIAL STONE SILICOSIS: THE ISRAEL EPIDEMIC, CURRENT VIEW].

  2017cited by this paper
• Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways.

  2017cited by this paper
• TGF&bgr; pathway inhibition in the treatment of non‐small cell lung cancer

  2017cited by this paper
• Sinusoidal communication in liver fibrosis and regeneration.

  2016cited by this paper
• TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis

  2016cited by this paper
• Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome.

  2016cited by this paper
• The rationale for targeting TGF‐β in chronic liver diseases

  2016cited by this paper
• Transforming growth factor beta (TGF‐β) isoforms in wound healing and fibrosis

  2016cited by this paper
• TGF-β1/Smads and miR-21 in Renal Fibrosis and Inflammation

  2016cited by this paper
• New frontiers in fibrotic disease therapies: The focus of the Joan and Joel Rosenbloom Center for Fibrotic Diseases at Thomas Jefferson University.

  2016cited by this paper
• TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology.

  2016cited by this paper
• CAF cellular glycolysis: linking cancer cells with the microenvironment

  2016cited by this paper
• Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.

  2016cited by this paper
• Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice

  2016cited by this paper
• Structural Basis of Intracellular TGF-β Signaling: Receptors and Smads.

  2016cited by this paper
• C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation

  2015cited by this paper
• Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge

  2015cited by this paper
• Targeting the TGFβ pathway for cancer therapy.

  2015cited by this paper
• Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

  2015cited by this paper
• miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program

  2015cited by this paper
• TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling

  2015cited by this paper
• MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis.

  2014cited by this paper
• The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis.

  2014cited by this paper
• TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.

  2013cited by this paper
• miR‐145 regulates myofibroblast differentiation and lung fibrosis

  2013cited by this paper
• RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms

  2013cited by this paper
• Idiopathic pulmonary fibrosis in Taiwan - a population-based study.

  2012cited by this paper
• Targeting the TGFβ signalling pathway in disease

  2012cited by this paper
• Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload.

  2012cited by this paper
• Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β.

  2012cited by this paper
• Differential Regulation of TGF-β/Smad Signaling in Hepatic Stellate Cells between Acute and Chronic Liver Injuries

  2012cited by this paper
• Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice.

  2012cited by this paper
• A common MUC5B promoter polymorphism and pulmonary fibrosis.

  2011cited by this paper

• Navigating thyroid hormone signaling in liver fibrosis: mechanisms and clinical implications.

  2026cites this paper
• Microfluidic innovations in chronic kidney disease and renal fibrosis: from mechanistic insights to clinical applications.

  2026cites this paper
• Sex hormone-binding globulin restrains hepatic fibrosis via inhibition of Tgfβ expression

  2025cites this paper
• In silico design of potent inhibitors targeting TNF-alpha, IL-1β, and TGF-β of inflammatory disease using QSAR, docking, MD simulation, ADMET, and DFT studies

  2025cites this paper
• Long-Term Corneal Reshaping Using Riboflavin–UVA Crosslinking Combined With Decorin in Rabbits

  2025cites this paper
• Structural insights and clinical advances in small-molecule inhibitors targeting TGF-β receptor I

  2025cites this paper
• Genome-wide CRISPR/Cas9 screening identifies key profibrotic regulators of TGF-β1-induced epithelial-mesenchymal transformation and pulmonary fibrosis

  2025cites this paper
• Radiation-Induced Fibrosis in Head and Neck Cancer: Challenges and Future Therapeutic Strategies for Vocal Fold Treatments

  2025cites this paper
• Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial

  2025cites this paper
• Molecular Pathways in Idiopathic Pulmonary Fibrosis: A Review of Novel Insights for Drug Design

  2025cites this paper
• Computational Drug Repurposing Screening Targeting Profibrotic Cytokine in Acute Respiratory Distress Syndrome

  2025cites this paper
• Mechanism of action and potential therapeutic targets of TGF-β-related signaling pathway and its downstream miRNA expression in pulmonary arterial hypertension

  2025cites this paper
• A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases

  2025cites this paper
• Effect of transforming growth factor beta receptor I inhibitors on myotube formation in vitro

  2025cites this paper
• Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis.

  2025cites this paper
• Breaking the cycle: should we target inflammation, fibrosis, or both?

  2025cites this paper
• Advances in JNK inhibitor development: therapeutic prospects in neurodegenerative diseases and fibrosis

  2025cites this paper
• 3D alveolar organoid drug screening model for targeting TGF-β1 in pulmonary fibrosis

  2025cites this paper
• Rewiring the scar: translational advances in cardiac fibrosis

  2025cites this paper
• miR-146b disrupts the epidermal growth factor receptor/transforming growth factor β receptor profibrotic feedforward loop to inhibit lung fibroblast proliferation and differentiation.

  2025cites this paper
• Propolis compound inhibits profibrotic TGF-β1/SMAD signalling in human fibroblasts

  2025cites this paper
• Bexotegrast Shows Dose-Dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial

  2024cites this paper
• Shared and Distinct Renal Transcriptome Signatures in 3 Standard Mouse Models of Chronic Kidney Disease

  2024cites this paper
• Innate and Adaptive Immune Responses in Intestinal Transplant Rejection: Through the Lens of Inflammatory Bowel and Intestinal Graft-Versus-Host Diseases.

  2024cites this paper
• Fibrosis‐on‐Chip: A Guide to Recapitulate the Essential Features of Fibrotic Disease

  2024cites this paper
• The clinical manifestations and molecular pathogenesis of radiation fibrosis

  2024cites this paper
• A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers

  2024cites this paper
• Progranulin: A promising biomarker and therapeutic target for fibrotic diseases

  2024cites this paper
• Colonic Tuft Cells: The Less-Recognized Therapeutic Targets in Inflammatory Bowel Disease and Colorectal Cancer

  2024cites this paper
• Impaired Tertiary Dentin Secretion after Shallow Injury in Tgfbr2-Deficient Dental Pulp Cells Is Rescued by Extended CGRP Signaling

  2024cites this paper
• SARS-CoV-2-related peptides induce endothelial-to-mesenchymal transition in endothelial capillary cells derived from different body districts: focus on membrane (M) protein

  2024cites this paper
• Cellular and Molecular Genetic Mechanisms of Lung Fibrosis Development and the Role of Vitamin D: A Review

  2024cites this paper
• Highly Selective Artificial K+ Transporters Reverse Liver Fibrosis In Vivo

  2024cites this paper
• Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three‐headed monster

  2024cites this paper
• Exploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer.

  2024cites this paper
• Activins and Inhibins in Cardiovascular Pathophysiology

  2024cites this paper
• Leveraging Machine Learning, Transformers, and Large-Scale Chemical Data to Predict TGF-β1 Inhibitors for Cardiac Fibrosis Treatment

  2024cites this paper
• Oxy210, a Semi-Synthetic Oxysterol, Inhibits Profibrotic Signaling in Cellular Models of Lung and Kidney Fibrosis

  2023cites this paper
• Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.

  2023cites this paper
• Hypoxia enhances anti-fibrotic properties of extracellular vesicles derived from hiPSCs via the miR302b-3p/TGFβ/SMAD2 axis

  2023cites this paper
• Dysregulation of transfer RNA-derived small RNAs that regulate cell activity and its related signaling pathways in human cancers.

  2023cites this paper
• Advances in biological and targeted therapies for systemic sclerosis

  2023cites this paper
• Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues

  2023cites this paper
• An agent-based modeling approach for lung fibrosis in response to COVID-19

  2022cites this paper
• Ivermectin Attenuates CCl4-Induced Liver Fibrosis in Mice by Suppressing Hepatic Stellate Cell Activation

  2022cites this paper
• Proteomic Insights into Cardiac Fibrosis: From Pathophysiological Mechanisms to Therapeutic Opportunities

  2022cites this paper
• Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells.

  2022cites this paper
• Exploration and study of downstream target proteins related to pancreatic cancer

  2022cites this paper
• Verbascoside and isoverbascoside ameliorate transforming growth factor β1-induced collagen expression by lung fibroblasts through Smad/non-Smad signaling pathways.

  2022cites this paper